Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02316314
Recruitment Status : Recruiting
First Posted : December 12, 2014
Last Update Posted : September 2, 2020
Sponsor:
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Brief Summary:
Friedreich's ataxia (FRDA) is an autosomal recessive disease characterized by loss of coordination and cardiomyopathy. It is the most common form of inherited ataxia with an incidence in 1/50,000 in the Caucasian population. FRDA is associated with progressive damage to the nervous system, resulting in symptoms ranging from gait disturbance to speech problems, as well as diabetes and heart disease. The heart disease manifests as cardiomyopathy, and is responsible for approximately 60% of deaths from FRDA. This study is designed to characterize the cardiac manifestations of the disease using exercise, MRI, ECHO and serum parameters, in the context of the neurological disease. In addition, this study will demonstrate that corneal confocal microscopy (CCM) may also provide a biomarker for FRDA.

Condition or disease Intervention/treatment
Friedreich's Ataxia Procedure: Cardiac magnetic resonance imaging (CMR) Procedure: Exercise-stress test Procedure: Echocardiogram (ECHO) Procedure: Cardiac-related blood studies

Detailed Description:
The focus of this study is to assess cardiac dysfunction in individuals with FRDA using 4 modalities: hand crank exercise, cardiac magnetic resonance (CMR) imaging, echocardiography (ECHO), and serum measurements of cardiac status, including high sensitivity troponin, a measure of cardiac myocyte damage; N-terminal prohormone of brain natriuretic peptide (NTproBNP), a measure of heart failure; and creatine phosphokinase (CPK), a general measure of muscle damage. While there have been individual studies of some of these modalities, there are no studies that correlate these parameters and it is not known which parameters are more sensitive to cardiac dysfunction. This preliminary study will help define the parameters most useful in assessing the cardiac involvement in FRDA. In addition, the study will investigate noninvasive tests and procedures that may serve as biomarkers for the neurologic disease. In other neurological diseases, non-invasive examination of the number and structure of nerve cells in the cornea has been assessed as an indication of disease progression.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 80 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)
Study Start Date : December 2014
Estimated Primary Completion Date : August 2023
Estimated Study Completion Date : December 2023


Group/Cohort Intervention/treatment
Individuals diagnosed with FRDA
Individuals diagnosed with FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies
Procedure: Cardiac magnetic resonance imaging (CMR)
CMR is a non-invasive way to take a high-resolution image of the heart and vessels. CMR uses powerful magnets and radio waves to obtain the image. During the CMR, you will have a substance injected into your vein called "contrast" to get a better picture of the heart.

Procedure: Exercise-stress test
You will be asked to pedal on a bicycle with your arms to see how much work you can do and how far you can go.

Procedure: Echocardiogram (ECHO)
An echocardiogram is an ultrasound of the heart done at rest.

Procedure: Cardiac-related blood studies
The blood test involves drawing blood from a vein in the arm by placing a needle in it. The total amount of blood to be drawn for a single visit will be up to 57 mL (12 teaspoons).

Healthy controls
Individuals without FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies
Procedure: Cardiac magnetic resonance imaging (CMR)
CMR is a non-invasive way to take a high-resolution image of the heart and vessels. CMR uses powerful magnets and radio waves to obtain the image. During the CMR, you will have a substance injected into your vein called "contrast" to get a better picture of the heart.

Procedure: Exercise-stress test
You will be asked to pedal on a bicycle with your arms to see how much work you can do and how far you can go.

Procedure: Echocardiogram (ECHO)
An echocardiogram is an ultrasound of the heart done at rest.

Procedure: Cardiac-related blood studies
The blood test involves drawing blood from a vein in the arm by placing a needle in it. The total amount of blood to be drawn for a single visit will be up to 57 mL (12 teaspoons).




Primary Outcome Measures :
  1. Level of troponin, BNP, and CPK in blood [ Time Frame: 30 minutes ]
    Average the levels of troponin for each subject

  2. echocardiogram [ Time Frame: 2 hour ]
    Evaluate the results of subject's Echo cardiograms

  3. exercise-stress test [ Time Frame: 2 hour ]
    Evaluate off the results of the exercise-stress test


Biospecimen Retention:   Samples With DNA

Blood Amount: Up to 105 mL of blood will be collected for the entire study and up to 65 mL of blood will be collected for a single visit. (CBC = 5 mL per visit; Clotting = 6 mL per visit; Chemistry = 7 mL per visit; Liver function = 5 mL per visit; Cardiac enzymes = 5 mL per visit; Neurologic enzymes = 8 mL per visit; Future serum = 3 mL per visit; Genetic analysis = 4 mL; HbA1c = 5mL; HIV test = 7 mL; and Anti-AAVrh.10 = 10 mL).

Urine Amount: Approximately 24 mL of urine will be collected for the entire study and approximately 12 mL of urine will be collected for a single visit.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The study will be composed of individuals with FRDA and individuals without FRDA. Individuals without FRDA will be age, gender and ethnicity matched to the individuals with FRDA.
Criteria

Friedreich's Ataxia - Inclusion Criteria:

  • Males and females, age 12 to 30
  • Willing and able to provide informed consent (adolescents will need to provide assent and a parent to provide consent)
  • Definitive diagnosis of FRDA, based on clinical phenotype and genotype
  • Left ventricle ejection fraction measured by ECHO of >35% (If results of an ECHO are not available for a potential subject, then an ECHO will first be performed and subjects with an LVEF <35% will not be required to perform the CPET)

Friedreich's Ataxia - Exclusion Criteria:

  • Signs and symptoms of cardiac failure
  • Moderate to severe atrial or ventricular arrythmias
  • History of angina pectoris
  • Implanted pacemaker and/ or defibrillator or any other device that would preclude MRI assessment
  • Any form of dialysis; Severe or end-stage CKD (CKD 4 or 5, eGFR < 30 ml/min/1.73 m2) without dialysis; eGFR 30 to 40 ml/min/1.73 m2 without dialysis; Acute kidney injury (If a recent assessment is not available, then a blood test to assess kidney function will be performed prior to cardiac MRI)
  • Females who are pregnant
  • Receipt of an investigational drug within 30 days or 5 half-lives, whichever is longer, prior to screening, or active enrollment in an investigational medication or device study
  • Unable to undergo cardiac MRI with gadolinium contrast or claustrophobia
  • Clinical history or evidence of Type 1 or Type 2 Diabetes mellitus
  • Any condition, disorder, or abnormal laboratory test findings at screening which, in the judgment of the investigator, would interfere with the individual's ability to comply with all study requirements, or would require the administration of treatment during the study that could potentially affect the interpretation of the study data, or would place the individual at an unacceptable risk by his/ her participation in the study

Normal controls - Inclusion Criteria:

  • Males and females, age 12 to 30
  • Willing and able to provide informed consent (Adolescents will need to provide assent and a parent to provide consent)
  • Matched age, gender and ethnicity to the FRDA group
  • Capable of undergoing the various modalities of cardiac assessment
  • Left ventricle ejection fraction measured by ECHO of >35% (If results of an ECHO are not available for a potential subject, then an ECHO will first be performed and subjects with an LVEF <35% will be withdrawn from the study)

Normal controls - Exclusion Criteria:

  • Individuals not deemed in good overall health by the investigator will not be accepted into the study
  • Signs and symptoms of cardiac failure
  • Moderate to severe atrial or ventricular arrhythmias
  • History of angina pectoris
  • Implanted pacemaker and/ or defibrillator or any other device that would preclude MRI assessment
  • Any form of dialysis; Severe or end-stage CKD (CKD 4 or 5, eGFR < 30 ml/min/1.73 m2) without dialysis; eGFR 30 to 40 ml/min/1.73 m2 without dialysis; Acute kidney injury (If a recent assessment is not available, then a blood test to assess kidney function will be performed prior to cardiac MRI)
  • Females who are pregnant or lactating
  • Receipt of an investigational drug within 30 days or 5 half-lives, whichever is longer, prior to screening, or active enrollment in an investigational medication or device study
  • Unable to sit with back support
  • Unable to undergo cardiac MRI with gadolinium contrast or claustrophobia
  • Unable to undergo exercise tests
  • Clinical history or evidence of Type 1 or Type 2 Diabetes mellitus
  • Any condition, disorder, or abnormal laboratory test findings at screening which, in the judgment of the investigator, would interfere with the individual's ability to comply with all study requirements, or would require the administration of treatment during the study that could potentially affect the interpretation of the study data, or would place the individual at an unacceptable risk by his/ her participation in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02316314


Contacts
Layout table for location contacts
Contact: Anisette Ruda, BA 646-962-2672 amr2034@med.cornell.edu

Locations
Layout table for location information
United States, New York
Weill Cornell Medicine Recruiting
New York, New York, United States, 10021
Contact: Anisette Ruda, BA    646-962-2672    amr2034@med.cornell.edu   
Contact: Grace W Mammen, MPA       gwm2004@med.cornell.edu   
Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Layout table for investigator information
Principal Investigator: Odelya Pagovich, MD Weill Cornell Medicine
Layout table for additonal information
Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT02316314    
Other Study ID Numbers: 1408015429
First Posted: December 12, 2014    Key Record Dates
Last Update Posted: September 2, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Weill Medical College of Cornell University:
Friedreich's Ataxia
Cardiomyopathy
FRDA
Ataxia
Additional relevant MeSH terms:
Layout table for MeSH terms
Ataxia
Cerebellar Ataxia
Friedreich Ataxia
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Cerebellar Diseases
Brain Diseases
Central Nervous System Diseases
Spinocerebellar Degenerations
Spinal Cord Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Mitochondrial Diseases
Metabolic Diseases